%0 Journal Article
%T Synergistic effect of folate and MTHFR C677T on hippocampal subfields and perfusion in Alzheimer's disease.
%A Tang Y
%A Zhou X
%A Cao J
%A Li Z
%A Yin W
%A Wan K
%A Huang C
%A Zhu W
%A Yin J
%A Zhang W
%A Zhu X
%A Sun Z
%J Prog Neuropsychopharmacol Biol Psychiatry
%V 134
%N 0
%D 2024 Jun 20
%M 38908503
%F 5.201
%R 10.1016/j.pnpbp.2024.111071
%X <B>BACKGROUND: </B>Low folate intake and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism have been suggested to increase the risk of Alzheimer's disease (AD). However, the synergistic effects and their impact on brain structure and perfusion remain unclear.<BR><B>METHODS: </B>This study explored the effects of dietary and genetic deficiencies in folate metabolism on the volume of the hippocampal subregions, cerebral perfusion, and cognitive decline in 71 cognitively unimpaired (CU) individuals and 102 patients with mild cognitive impairment (MCI) due to AD or AD. All participants underwent magnetic resonance imaging, laboratory examinations, and neuropsychological assessments. The hippocampal subfields were segmented using Freesurfer, and arterial spin labeling was used to measure the cerebral blood flow.<BR><B>RESULTS: </B>We found a significant group-by-MTHFR interaction effect on folate. Patients with AD and the 677 T allele showed hypoperfusion in the left precuneus compared to patients without this mutation, which mediated the relationship between low folate level and cognitive decline in patients carrying the 677 T allele. Moreover, a synergistic effect was observed for the combination of decreased folate concentrations and the presence of the MTHFR 677 T allele on the atrophy of specific hippocampal subregions in patients with AD.<BR><B>CONCLUSIONS: </B>In addition to offering insights into the neuronal mechanism underlying gene-dependent folate-induced cognitive impairment in AD, these findings may have clinical significance for the allocation of auxiliary folate supplementation therapy in patients with AD with low folate levels and carrying the MTHFR 677 T allele and may eventually promote the selection of early individualized AD drug therapy.